BGE-102
Cardiovascular Risk and Metabolic Dysfunction
Key Facts
About BioAge Labs
BioAge Labs harnesses aging biology to develop novel therapies for obesity and metabolic diseases through their proprietary multi-omics discovery platform. Their lead candidate BGE-102 targets NLRP3-mediated inflammation, while their APJ program aims to mimic exercise benefits for obesity treatment. The company recently completed a $115 million public offering and trades on NASDAQ under ticker BIOA.
View full company profileAbout BioAge Labs
BioAge Labs harnesses aging biology to develop novel therapies for obesity and metabolic diseases through their proprietary multi-omics discovery platform. Their lead candidate BGE-102 targets NLRP3-mediated inflammation, while their APJ program aims to mimic exercise benefits for obesity treatment. The company recently completed a $115 million public offering and trades on NASDAQ under ticker BIOA.
View full company profile